Colon Cancer

Drug shows some good results

Published in Cancer Weekly, June 10th, 2003

An experimental drug that had essentially been written off as a failure dramatically extended the lives of some of the sickest colon cancer patients, its maker, Genentech, Inc., says.

The news sent the biotechnology company's stock soaring nearly 45% and boosted the spirits of researchers working with similar drugs in a field plagued by recent setbacks.

Genentech's Avastin is the most advanced drug in this new class of medicines, which are intended to choke off the blood supply to cancer tumors. The work was pioneered by Dr. Judah Folkman some 30 years ago.

"The fact that this extended life is a very major medical breakthrough,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry